Skip to main content

Table 1 ANXA1 expression and clinical variables

From: Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis

 

BCAC patients

 

BRCA1|2 mutation carriers

 

ANXA1 negative

ANXA1 positive

ANXA1 negative

ANXA1 positive

n

%

n

%

P valuea

n

%

n

%

P valueb

P valuec

5,040

87.6

712

12.4

 

55

51.4

52

48.6

 

<0.0001

Age of diagnosis

    

<0.0001

    

0.2253

0.0401

 <50 years old

2,462

85.6

413

14.4

 

34

47.2

38

52.8

  

 ≥50 years old

2,578

89.6

299

10.4

21

60.0

14

40.0

 Missing

0

 

0

  

0

 

0

   

BRCA status

    

0.0026

    

0.0583

 

 Non-carrier

858

83.6

168

16.4

       

  BRCA1

11

61.1

7

38.9

25

42.4

34

57.6

 

  BRCA2

14

73.7

5

26.3

30

62.5

18

37.5

 Missing

3,812

 

430

  

0

 

0

   

Menopausal status

    

0.0330

      

 Pre-

1,556

86.2

250

13.8

       

 Post-

2,258

88.3

298

11.7

    

 Missing

1,226

 

164

        

Morphology

    

<0.0001

    

0.5946

0.0235

 Ductal

3,558

86.2

568

13.8

 

33

50.8

32

49.2

  

 Lobular

710

94.3

43

5.7

11

61.1

7

38.9

 Missing

772

 

101

  

11

 

13

   

Grade

    

<0.0001

    

0.0040

0.1460

 1

1,129

95.0

59

5.0

 

7

77.8

2

22.2

  

 2

2,246

92.8

173

7.2

26

66.7

13

33.3

 3

1,306

75.2

431

24.8

19

35.8

34

64.2

 Missing

359

 

49

  

3

 

3

   

Tumor size

    

<0.0001

    

0.9910

0.7780

 ≤2 cm

2,809

88.8

354

11.2

 

31

51.7

29

48.3

  

 >2 cm and ≤5 cm

1,610

86.5

252

13.5

19

52.8

17

47.2

 >5 cm

109

79.9

29

21.0

2

50.0

2

50

 Missing

512

 

77

 

3

 

4

 

Node status

    

0.2725

      

 Negative

2,669

87.1

395

12.9

 

31

47.0

35

53.0

0.3044

0.1790

 Positive

1,955

88.1

263

11.9

 

22

59.5

15

40.5

  

 Missing

416

 

54

 

2

 

2

 

ER status

    

<0.0001

      

 Negative

977

67.8

465

32.2

 

13

28.3

33

71.7

<0.0001

0.7373

 Positive

3,796

95.0

200

5.0

 

36

75.0

12

25.0

  

 Missing

267

 

47

 

6

 

7

 

PR status

    

<0.0001

      

 Negative

1,435

75.9

455

24.1

 

20

35.1

37

64.9

<0.0001

0.1670

Positive

3,159

94.8

175

5.2

 

27

77.1

8

22.9

  

 Missing

446

 

82

 

8

 

7

 

HER2 status

    

0.1328

      

 Negative

3,484

88.7

442

11.3

 

25

48.1

27

51.9

1.0000

0.0684

 Positive

643

86.8

98

13.2

 

1

50.0

1

50.0

  

 Missing

913

 

172

 

29

 

24

 

EGFR-CK5/6 statusd

    

<0.0001

      

 Negative

3,317

93.8

218

6.2

       

 Positive

541

67.6

259

32.4

       

 Missing

1,182

 

235

     

p53 statuse

    

0.0572

      

 Negative

172

90.1

19

9.9

 

17

45.9

20

54.1

0.0211

0.8116

 Positive

57

80.3

14

19.7

 

3

14.3

18

85.7

  

 Missing

596

 

89

 

35

 

14

 

Adjuvant chemotherapy

    

<0.0001

      

 No

2,593

89.9

282

10.1

       

 Yes

1,585

83.2

320

16.8

       

 Missing

862

 

100

     

Adjuvant hormonal therapy

    

<0.0001

      

 No

2,059

82.5

438

17.5

       

 Yes

2,562

92.6

204

7.4

       

 Missing

419

 

70

       
  1. Distribution of the clinical variables in breast cancer patients according to the ANXA1 expression in all invasive tumors from the BCAC and BRCA1|2 set of patients
  2. ANXA1 annexin A1, BCAC Breast Cancer Association Consortium, EGFR epidermal growth factor receptor
  3. aP value of the comparison between ANXA1 positive and negative patients in the BCAC set
  4. bP value of the comparison between ANXA1 positive and negative patients in the BRCA1|2 mutated set
  5. cP value of the comparison between the two sets of ANXA1 positive patients: BCAC and BRCA1|2 mutated patients
  6. dEGFR-CK5/6 status was defined as positive when CK5/6 and/or EGFR were positive
  7. ein the BCAC set, p53 status information was only available for the ABCS study
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us